About Beijing Centergate Technologies Company

The company was founded in 1999 and listed on the Shenzhen Stock Exchange. In 2015, the company's industrial pattern gradually changed from “technology real estate+medicine” to a development and management strategy centered on “medicine and health”. In August 2018, the company was approved by the regulatory authorities, and the industry classification was changed from “comprehensive” to “pharmaceutical manufacturing”, and the strategic transformation was initially successful. In August 2021, the company adjusted its development strategy and further focused on positioning, and plans to establish an innovative pharmaceutical industry group focusing on the pharmaceutical field. The company's business is mainly divided into biomedicine and health products business, nursing care business, commercial concrete business and other businesses. The company's main products and business include saponin BII and capsules, biphenylbenzazole cream and raw materials, naloxone hydrochloride injections, benidipine hydrochloride tablets, glipyrazine dispersion tablets, aminophen tramadol tablets, montmorillonitrile, toranisetron mesylate injections, bisoprolol fumarate tablets, silidiol tablets, phenyclononyl hydrochloride tablets, oxycodone hydrochloride injections, citrulline tablets, lactic acid trimazole injections, tramadol hydrochloride tablets and APIs, clindamycin phosphate vaginal gel, piracetam injections, acanthurium injections, centralized nursing services, home care Services, health management, health consultation, preventive health consultation, traditional Chinese medicine medical services, concrete, cement products, electronic store management, property management services, hotel services, investment, etc.